|
References
1.Stanley JA, Pettegrew JW, Keshavan MS. Magnetic
resonance spectroscopy in schizophrenia: Methodological issues and
findings-part I. Biol Psychiatry 2000;48:357–68.
2.Farrar TC, Becker ED. Pulse and Fourier transform
NMR; introduction to theory and methods. New York: Academic Press;
1971.
3.Fukushima E, Roeder SBW. Experimental pulse NMR:
a nuts and bolts approach. Reading (MA): Addison-Wesley Pub. Co.
Advanced Book Program; 1981.
4.Gadian DG. NMR and its applications to living
systems. 2nd ed. New York: Oxford University Press; 1995.
5.Coyle JT. The nagging question of the function
of N-acetylaspartylglutamate. Neurobiol Dis 1997;4:231–8.
6.Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric
disorders. Prog Neurobiol 1995;46:531–40.
7.Magistretti PJ, Pellerin L. Cellular mechanisms
of brain energy metabolism and their relevance to functional brain
imaging. Philos Trans R Soc Lond B Biol Sci 1999;354:1155–63.
8.Rothman DL, Sibson NR, Hyder F, Shen J, Behar
KL, Shulman RG. In vivo nuclear magnetic resonance spectroscopy
studies of the relationship between the glutamate- glutamine neurotransmitter
cycle and functional neuroenergetics. Philos Trans R Soc Lond B
Biol Sci 1999;354:1165–77.
9.Michaelis T, Merboldt KD, Bruhn H, Hanicke W,
Frahm J. Absolute concentrations of metabolites in the adult human
brain in vivo: Quantification of localized proton MR spectra. Radiology
1993;187:219–27.
10.Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke
W, Sauter R. Localized proton NMR spectroscopy in different regions
of the human brain in vivo. Relaxation times and concentrations
of cerebral metabolites. Magn Reson Med 1989;11:47–63.
11.Bessman SP, Geiger PJ. Transport of energy in
muscle: The phosphorylcreatine shuttle. Science 1981;211:448–52.
12.Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger
HM. Intracellular compartmentation, structure and function of creatine
kinase isoenzymes in tissues with high and fluctuating energy demands:
The ‘phosphocreatine circuit’ for cellular energy homeostasis.
Biochem J 1992;281:21–40.
13.Dawson RMC. Enzymatic pathways of phospholipid
metabolism in the nervous system. In: Eichberg J, editor. Phospholipids
in nervous tissues. New York: Wiley; 1985:45–78.
14.Pettegrew JW, Kopp SJ, Minshew NJ, Glonek T,
Feliksik JM, Tow JP, and others. 31P nuclear magnetic resonance
studies of phosphoglyceride metabolism in developing and degenerating
brain: Preliminary observations. J Neuropathol Exp Neurol 1987;46:419–30.
15.Geddes JW, Pandey GN, Keller JN, Pettegrew JW.
Elevated phosphocholine and phosphatidyl choline following rat entorhinal
cortex lesions. Neurobiol Aging 1997;18:305–8.
16.Miller BL. A review of chemical issues in 1H
NMR spectroscopy: N-acetyl-l- aspartate, creatine and choline. NMR
Biomed 1991;4:47–52.
17.Hetherington HP, Pan JW, Mason GF, Ponder SL,
Twieg DB, Deutsch G, and others. 2d 1H spectroscopic imaging of
the human brain at 4.1 T. Magn Reson Med 1994;32:530–4.
18.Prost RW, Mark L, Mewissen M, Li SJ. Detection
of glutamate/glutamine resonances by 1H magnetic resonance spectroscopy
at 0.5 tesla. Magn Reson Med 1997;37:615–8.
19.Bartha R, Drost DJ, Menon RS, Williamson PC.
Comparison of the quantification precision of human short echo time
(1)h spectroscopy at 1.5 and 4.0 tesla. Magn Reson Med 2000;44:185–92.
20.Barker PB, Hearshen DO, Boska MD. Single-voxel
proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 2001;45:765–9.
21.Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil
K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at
7 T. Magn Reson Med 2001;46:451–6.
22.Bottomley PA. Spatial localization in NMR spectroscopy
in vivo. Ann N Y Acad Sci 1987;508:333–48.
23.Ordidge RJ, Connelly A, Lohman JB. Image-selected
in vivo spectroscopy (ISIS). A new technique for spatially selective
NMR spectroscopy. J Magn Reson 1986;66:283–94.
24.Merboldt KD, Chien D, Hanicke W, Gyngell ML,
Bruhn H, Frahm J. Localized 31P NMR spectroscopy of the adult human
brain in vivo using stimulated-echo (STEAM) sequences. J Magn Reson
1990;89:343–61.
25.Lim KO, Pauly J, Webb P, Hurd R, Macovski A.
Short TE phosphorus spectroscopy using a spin-echo pulse. Magn Reson
Med 1994;32:98–103.
26.Brown TR. Practical applications of chemical
shift imaging. NMR Biomed 1992;5:238–43.
27.Stanley JA, Pettegrew JW. A post-processing method
to segregate and quantify the broad components underlying the phosphodiester
spectral region of in vivo 31P brain spectra. Magn Reson Med 2001;45:390–6.
28.Murphy EJ, Bates TE, Williams SR, Watson T, Brindle
KM, Rajagopalan B, and others. Endoplasmic reticulum: the major
contributor to the pde peak in hepatic 31P-NMR spectra at low magnetic
field strengths. Biochim Biophys Acta 1992;1111:51–8.
29.Murphy EJ, Rajagopalan B, Brindle KM, Radda GK.
Phospholipid bilayer contribution to 31P NMR spectra in vivo. Magn
Reson Med 1989;12:282–9.
30.Kilby PM, Allis JL, Radda GK. Spin-spin relaxation
of the phosphodiester resonance in the 31P NMR spectrum of human
brain. The determination of the concentrations of phosphodiester
components. FEBS Lett 1990;272:163–5.
31.Kilby PM, Bolas NM, Radda GK. 31P-NMR study of
brain phospholipid structures in vivo. Biochim Biophys Acta 1991;1085:257–64.
32.Pettegrew JW, Panchalingam K, Klunk WE, McClure
RJ, Muenz LR. Alterations of cerebral metabolism in probable Alzheimer’s
disease: A preliminary study. Neurobiol Aging 1994;15:117–32.
33.Patel TB, Clark JB. Synthesis of N-acetyl-l-aspartate
by rat brain mitochondria and its involvement in mitochondrial/cytosolic
carbon transport. Biochem J 1979;184:539–46.
34.Truckenmiller ME, Namboodiri MAA, Brownstein
MJ, Neale JH. N-acetylation of l-aspartate in the nervous system:
differential distribution of a specific enzyme. J Neurochem 1985;45:1658–62.
35.Koller KJ, Zaczek R, Coyle J. N-acetyl-aspartyl-glutamate:
regional levels in rat brain and the effects of brain lesions as
determined by a new hplc method. J Neurochem 1984;43:1136–42.
36.Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical
localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience
1991;45:37–45.
37.Nadler JV, Cooper JR. N-acetyl-l-aspartic acid
content of human neural tumours and bovine peripheral nervous tissues.
J Neurochem 1972;19:313–9.
38.Moffett JR, Namboodiri MA, Cangro CB, Neale JH.
Immunohistochemical localization of N-acetylaspartate in rat brain.
Neuroreport 1991;2:131–4.
39.Urenjak J, Williams SR, Gadian DG, Noble M. Proton
nuclear magnetic resonance spectroscopy unambiguously identifies
different neural cell types. J Neurosci 1993;13:981–9.
40.Matalon R, Michals K, Sebesta D, Deanching M,
Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic
aciduria in patients with Canavan disease. Am J Med Genet 1988;29:463–71.
41.Shaag A, Anikster Y, Christensen E, Glustein
JZ, Fois A, Michelakakis H, and others. The molecular basis of canavan
(aspartoacylase deficiency) disease in European non-Jewish patients.
Am J Hum Genet 1995;57:572–80.
42.Baslow MH, Resnik TR. Canavan disease. Analysis
of the nature of the metabolic lesions responsible for development
of the observed clinical symptoms. J Mol Neurosci 1997;9:109–25.
43.De Stefano N, Matthews PM, Arnold DL. Reversible
decreases in N-acetylaspartate after acute brain injury. Magn Reson
Med 1995;34:721–7.
44.Jagannathan NR, Tandon N, Raghunathan P, Kochupillai
N. Reversal of abnormalities of myelination by thyroxine therapy
in congenital hypothyroidism: Localized in vivo proton magnetic
resonance spectroscopy (MRS) study. Brain Res Dev Brain Res 1998;109:179–86.
45.Bhakoo KK, Pearce D. In vitro expression of N-acetyl
aspartate by oligodendrocytes: Implications for proton magnetic
resonance spectroscopy signal in vivo. J Neurochem 2000;74:254–62.
46.Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen
RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin
lipid synthesis: Evidence for myelin-associated aspartoacylase.
J Neurochem 2001;78:736–45.
47.Bhakoo KK, Craig TJ, Styles P. Developmental
and regional distribution of aspartoacylase in rat brain tissue.
J Neurochem 2001;79:211–20.
48.Baslow MH. Functions of N-acetyl-l-aspartate
and N-acetyl-l-aspartylglutamate in the vertebrate brain: role in
glial cell-specific signaling. J Neurochem 2000;75:453–9.
49.Baslow MH. Evidence supporting a role for N-acetyl-l-aspartate
as a molecular water pump in myelinated neurons in the central nervous
system. An analytical review. Neurochem Int 2002;40:295–300.
50.Govindaraju V, Young K, Maudsley AA. Proton NMR
chemical shifts and coupling constants for brain metabolites. NMR
Biomed 2000;13:129–53.
51.Rothman DL, Petroff OA, Behar KL, Mattson RH.
Localized 1H NMR measurements of gamma-aminobutyric acid in human
brain in vivo. Proc Natl Acad Sci U S A 1993;90:5662–6.
52.Wilman AH, Allen PS. Yield enhancement of a double-quantum
filter sequence designed for the edited detection of gaba. J Magn
Reson B 1995;109:169–74.
53.Keltner JR, Wald LL, Frederick BD, Renshaw PF.
In vivo detection of gaba in human brain using a localized double-quantum
filter technique. Magn Reson Med 1997;37:366–71.
54.Allen PS, Thompson RB, Wilman AH. Metabolite-specific
NMR spectroscopy in vivo. NMR Biomed 1997;10:435–44.
55.Hao L, Peeling J. Simultaneous spectral editing
for gamma -aminobutyric acid and taurine using double quantum coherence
transfer. J Magn Reson 2000;143:95–100.
56.Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder
F, Petroff OA, and others. Reduced cortical gamma-aminobutyric acid
levels in depressed patients determined by proton magnetic resonance
spectroscopy. Arch Gen Psychiatry 1999;56:1043–7.
57.Sanacora G, Mason GF, Krystal JH. Impairment
of gabaergic transmission in depression: new insights from neuroimaging
studies. Crit Rev Neurobiol 2000;14:23–45.
58.Goddard AW, Mason GF, Almai A, Rothman DL, Behar
KL, Petroff OA, and others. Reductions in occipital cortex gaba
levels in panic disorder detected with 1H-magnetic resonance spectroscopy.
Arch Gen Psychiatry 2001;58:556–61.
59.Trabesinger AH, Weber OM, Duc CO, Boesiger P.
Detection of glutathione in the human brain in vivo by means of
double quantum coherence filtering. Magn Reson Med 1999;42:283-9.
60.Meister A, Anderson ME. Glutathione. Annu Rev
Biochem 1983;52:711–60.
61.Mahadik SP, Mukherjee S. Free radical pathology
and antioxidant defense in schizophrenia: a review. Schizophr Res
1996;19:1–17.
62.Do KQ, Trabesinger AH, M. K-K, Lauer CJ, Dydak
U, Hell D, and others. A unified hypothesis of schizophrenia based
on glutathione deficit. [abstract]. Biol Psychiatry 1999;45:42.
63.Andreasen NC. A unitary model of schizophrenia
bleuler’s “fragmented phrene” as schizencephaly.
Arch Gen Psychiatry 1999;56:781–7.
64.McCarley RW, Wible CG, Frumin M, Hirayasu Y,
Levitt JJ, Fischer IA, and others. MRI anatomy of schizophrenia.
Biol Psychiatry 1999;45:1099–119.
65.Ross CA, Pearlson GD. Schizophrenia, the heteromodal
association neocortex and development: Potential for a neurogenetic
approach. Trends Neurosci 1996;19:171–6.
66.Andreasen NC, Rezai K, Alliger R, Swayze VW,
2nd, Flaum M, Kirchner P, and others. Hypofrontality in neuroleptic-naive
patients and in patients with chronic schizophrenia. Assessment
with xenon 133 single-photon emission computed tomography and the
tower of london. Arch Gen Psychiatry 1992;49:943–58.
67.Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical
sensitization in the pathophysiology of schizophrenia: deficits
and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology
1997;17:205–29.
68.Farber NB, Newcomer JW, Olney JW. The glutamate
synapse in neuropsychiatric disorders. Focus on schizophrenia and
alzheimer’s disease. Prog Brain Res 1998;116:421–37.
69.Keshavan MS. Development, disease and degeneration
in schizophrenia: a unitary pathophysiological model. J Psychiatr
Res 1999;33:513–21.
70.Lewis DA. Schizophrenia and disordered neural
circuitry. Schizophr Bull 1997;23:529–31.
71.Fenton WS, Hibbeln J, Knable M. Essential fatty
acids, lipid membrane abnormalities, and the diagnosis and treatment
of schizophrenia. Biol Psychiatry 2000;47:8–21.
72.Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental
disorder? Br Med J 1987;295:681–2.
73.Weinberger Dr From neuropathology to neurodevelopment.
Lancet 1995;346:552–7.
74.Marenco S, Weinberger DR The neurodevelopmental
hypothesis of schizophrenia: following a trail of evidence from
cradle to grave. Dev Psychopathol 2000;12:501–27.
75.Feinberg I. Schizophrenia and late maturational
brain changes in man. Psychopharmacol Bull 1982;18:29–31.
76.Hoffman RE, McGlashan TH. Parallel distributed
processing and the emergence of schizophrenic symptoms. Schizophr
Bull 1993;19:119–40.
77.Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia
due to excessive synaptic pruning in the prefrontal cortex? J Psychiatr
Res 1994;28:239–65.
78.Pettegrew JW, Keshavan MS, Panchalingam K, Strychor
S, Kaplan DB, Tretta MG, and others. Alterations in brain high-energy
phosphate and membrane phospholipid metabolism in first-episode,
drug-naive schizophrenics. A pilot study of the dorsal prefrontal
cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.
Arch Gen Psychiatry 1991;48:563–8.
79.Selemon LD, Goldman-Rakic PS. The reduced neuropil
hypothesis: a circuit based model of schizophrenia. Biol Psychiatry
1999;45:17–25.
80.Williamson P, Drost D, Stanley J, Carr T, Morrison
S, Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy
in chronic schizophrenic patients and normal controls [letter].
Arch Gen Psychiatry 1991;48:578.
81.Stanley JA, Williamson PC, Drost DJ, Carr TJ,
Rylett RJ, Malla A, and others. An in vivo study of the prefrontal
cortex of schizophrenic patients at different stages of illness
via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry
1995;52:399–406.
82.Fukuzako H, Fukuzako T, Hashiguchi T, Kodama
S, Takigawa M, Fujimoto T. Changes in levels of phosphorus metabolites
in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry
1999;156:1205–8.
83.Stanley JA, Keshavan MS, Panchalingam K, McClure
RJ, Pettegrew JW. Membrane phospholipid metabolite alterations in
prefrontal and basal ganglia regions in schizophrenia: An in vivo
31P and 1H MRSI study. Proceedings of the 9th Annual meeting of
the International Society of Magnetic Resonance in Medicine. 2001;
ISMRM: Berkeley (CA). p1016.
84.Potwarka JJ, Drost DJ, Williamson PC, Carr T,
Canaran G, Rylett WJ, and others. A 1H-decoupled 31P chemical shift
imaging study of medicated schizophrenic patients and healthy controls.
Biol Psychiatry 1999;45:687–93.
85.Keshavan MS, Stanley JA, Pettegrew JW. Magnetic
resonance spectroscopy in schizophrenia: methodological issues and
findings-part II. Biol Psychiatry 2000;48:369–80.
86.Pettegrew JW, Keshavan MS, Minshew NJ. 31P nuclear
magnetic resonance spectroscopy: Neurodevelopment and schizophrenia.
Schizophr Bull 1993;19:35–53.
87.Klemm S, Rzanny R, Riehemann S, Volz HP, Schmidt
B, Gerhard UJ, and others. Cerebral phosphate metabolism in first-degree
relatives of patients with schizophrenia. Am J Psychiatry. 2001;158:958–60.
88.Stanley JA, Pettegrew JW, Panchalingam K, McClure
RJ, Harenski K, Montrose M, and others. Altered membrane phospholipid
metabolism in both offsprings of schizophrenia parents and in first-episode
never medicated schizophrenia subjects: An in vivo 31P MRS study.
Society for Neuroscience Abstracts 2000;26:1575.
89.Stanley JA, Williamson PC, Drost DJ, Rylett RJ,
Carr TJ, Malla A, and others. An in vivoproton magnetic resonance
spectroscopy study of schizophrenia patients. Schizophr Bull 1996;22:597–609.
90.Bartha R, Williamson PC, Drost DJ, Malla A, Carr
TJ, Cortese L, and others. Measurement of glutamate and glutamine
in the medial prefrontal cortex of never-treated schizophrenic patients
and healthy controls by proton magnetic resonance spectroscopy.
Arch Gen Psychiatry 1997;54:959–65.
91.Bartha R, al-Semaan YM, Williamson PC, Drost
DJ, Malla AK, Carr TJ, and others. A short echo proton magnetic
resonance spectroscopy study of the left mesial-temporal lobe in
first-onset schizophrenic patients. Biol Psychiatry 1999;45:1403–11.
92.Provencher SW. Estimation of metabolite concentrations
from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–9.
93.Stanley JA, Drost DJ, Williamson PC, Thompson
RT. The use of a priori knowledge to quantify short echo in vivo
1H MR spectra. Magn Reson Med 1995;34:17–24.
94.Bartha R, Drost DJ, Williamson PC. Factors affecting
the quantification of short echo in- vivo 1H MR spectra: Prior knowledge,
peak elimination, and filtering. NMR Biomed 1999;12:205–16.
95.Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton
magnetic resonance spectroscopy in the frontal and temporal lobes
of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology
1999;20:131–40.
96.Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum
A. Progressive brain volume changes and the clinical course of schizophrenia
in men: A longitudinal magnetic resonance imaging study. Arch Gen
Psychiatry 2001;58:148–57.
97.Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal
J, Nicolson R, and others. Mapping adolescent brain change reveals
dynamic wave of accelerated gray matter loss in very early-onset
schizophrenia. Proc Natl Acad Sci U S A 2001;98:11650–5.
98.Norris SD, Krishnan KR, Ahearn E. Structural
changes in the brain of patients with bipolar affective disorder
by MRI: a review of the literature. Prog Neuropsychopharmacol Biol
Psychiatry 1997;21:1323–37.
99.Altshuler LL, Bartzokis G, Grieder T, Curran
J, Jimenez T, Leight K, and others. An MRI study of temporal lobe
structures in men with bipolar disorder or schizophrenia. Biol Psychiatry
2000;48:147–62.
100.Drevets WC. Functional neuroimaging studies
of depression: The anatomy of melancholia. Annu Rev Med 1998;49:341–61.
101.Liotti M, Mayberg HS. The role of functional
neuroimaging in the neuropsychology of depression. J Clin Exp Neuropsychol
2001;23:121–36.
102.Strakowski SM, DelBello MP, Adler C, Cecil DM,
Sax KW. Neuroimaging in bipolar disorder. Bipolar Disord 2000;2:148–64.
103.Soares JC, Mann JJ. The anatomy of mood disorders—review
of structural neuroimaging studies. Biol Psychiatry 1997;41:86–106.
104.Dupont RM, Jernigan TL, Gillin JC, Butters N,
Delis DC, Hesselink JR. Subcortical signal hyperintensities in bipolar
patients detected by MRI. Psychiatry Res 1987;21:357–8.
105.Altshuler LL, Curran JG, Hauser P, Mintz J,
Denicoff K, Post R. T2 hyperintensities in bipolar disorder: Magnetic
resonance imaging comparison and literature meta-analysis. Am J
Psychiatry1995;152:1139–44.
106.Ketter TA, Andreason PJ, George MS, Lee C, Gill
DS, Parekh PI, and others. Anterior paralimbic mediation of procaine-induced
emotional and psychosensory experiences. Arch Gen Psychiatry 1996;53:59–69.
107.George MS, Ketter TA, Post RM. SPECT and PET
imaging in mood disorders. J Clin Psychiatry 1993;54 (Suppl):6–13.
108.Soares JC, Mann JJ. The functional neuroanatomy
of mood disorders. J Psychiatr Res 1997;31:393–432.
109.Kato T, Takahashi S, Shioiri T, Inubushi T.
Brain phosphorous metabolism in depressive disorders detected by
phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1992;26:223–30.
110.Kato T, Takahashi S, Shioiri T, Inubushi T.
Alterations in brain phosphorous metabolism in bipolar disorder
detected by in vivo 31P and 7Li magnetic resonance spectroscopy.
J Affect Disord 1993;27:53–9.
111.Deicken RF, Fein G, Weiner MW. Abnormal frontal
lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry
1995;152:915–8.
112.Deicken RF, Weiner MW, Fein G. Decreased temporal
lobe phosphomonoesters in bipolar disorder. J Affect Disord 1995;33:195–9.
113.Kato T, Shioiri T, Takahashi S, Inubushi T.
Measurement of brain phosphoinositide metabolism in bipolar patients
using in vivo 31P-MRS. J Affect Disord 1991;22:185–90.
114.Kato T, Shioiri T, Murashita J, Hamakawa H,
Takahashi Y, Inubushi T, and others. Lateralized abnormality of
high energy phosphate metabolism in the frontal lobes of patients
with bipolar disorder detected by phase- encoded 31P-MRS. Psychol
Med 1995;25:557–66.
115.Kato T, Takahashi S, Shioiri T, Murashita J,
Hamakawa H, Inubushi T. Reduction of brain phosphocreatine in bipolar
II disorder detected by phosphorus-31 magnetic resonance spectroscopy.
J Affect Disord 1994;31:125–33.
116.Sharma R, Venkatasubramanian PN, Barany M, Davis
JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic
and affective patients. Schizophr Res 1992;8:43–9.
117.Kato T, Hamakawa H, Shioiri T, Murashita J,
Takahashi Y, Takahashi S, and others. Choline-containing compounds
detected by proton magnetic resonance spectroscopy in the basal
ganglia in bipolar disorder. J Psychiatry Neurosci 1996;21:248–54.
118.Hamakawa H, Kato T, Murashita J, Kato N. Quantitative
proton magnetic resonance spectroscopy of the basal ganglia in patients
with affective disorders. Eur Arch Psychiatry Clin Neurosci 1998;248:53–8.
119.Moore CM, Breeze JL, Gruber SA, Babb SM, Frederick
BB, Villafuerte RA, and others. Choline, myo-inositol and mood in
bipolar disorder: A proton magnetic resonance spectroscopic imaging
study of the anterior cingulate cortex. Bipolar Disord 2000;2:207–16.
120.Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai
M, Takeda H, and others. Proton magnetic resonance spectroscopy
of the lenticular nuclei in bipolar i affective disorder. Psychiatry
Res 1998;84:55–60.
121.Winsberg ME, Sachs N, Tate DL, Adalsteinsson
E, Spielman D, Ketter TA. Decreased dorsolateral prefrontal N-acetyl
aspartate in bipolar disorder. Biol Psychiatry 2000;47:475–81.
122.Deicken RF, Eliaz Y, Feiwell R, Schuff N. Increased
thalamic N-acetylaspartate in male patients with familial bipolar
i disorder. Psychiatry Res 2001;106:35–45.
123.Yildiz A, Sachs GS, Dorer DJ, Renshaw PF. 31P
nuclear magnetic resonance spectroscopy findings in bipolar illness:
a meta-analysis. Psychiatry Res 2001;106:181–91.
124.Kato T, Shioiri T, Murashita J, Hamakawa H,
Inubushi T, Takahashi S. Phosphorus-31 magnetic resonance spectroscopy
and ventricular enlargement in bipolar disorder. Psychiatry Res
1994;55:41–50.
125.Kato T, Inubushi T, Kato N. Magnetic resonance
spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci
1998;10:133–47.
126.Berridge MJ, Irvine RF. Inositol phosphates
and cell signalling. Nature 1989;341:197–205.
127.Berridge MJ, Downes CP, Hanley MR. Neural and
developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411–9.
128.Berridge MJ, Downes CP, Hanley MR. Lithium amplifies
agonist-dependent phosphatidylinositol responses in brain and salivary
glands. Biochem J 1982;206:587–95.
129.Castillo M, Kwock L, Courvoisie H, Hooper SR.
Proton MR spectroscopy in children with bipolar affective disorder:
Preliminary observations. AJNR Am J Neuroradiol 2000;21:832–8.
130.Davanzo P, Thomas MA, Yue K, Oshiro T, Belin
T, Strober M, and others. Decreased anterior cingulate myo-inositol/creatine
spectroscopy resonance with lithium treatment in children with bipolar
disorder. Neuropsychopharmacology 2001;24:359–69.
131.Volz HP, Rzanny R, Riehemann S, May S, Hegewald
H, Preussler B, and others. 31P magnetic resonance spectroscopy
in the frontal lobe of major depressed patients. Eur Arch Psychiatry
Clin Neurosci 1998;248:289–95.
132.Moore CM, Christensen JD, Lafer B, Fava M, Renshaw
PF. Lower levels of nucleoside triphosphate in the basal ganglia
of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy
study. Am J Psychiatry 1997;154:116–8.
133.Pettegrew JW, Levine J, Gershon S, Stanley JA,
Servan-Schreiber D, Panchalingam K, and others. 31P-MRS study of
acetyl-l-carnitine treatment in geriatric depression: preliminary
results. Bipolar Disorders 2002; forthcoming.
134.Auer DP, Putz B, Kraft E, Lipinski B, Schill
J, Holsboer F. Reduced glutamate in the anterior cingulate cortex
in depression: An in vivo proton magnetic resonance spectroscopy
study. Biol Psychiatry 2000;47:305–13.
135.American Psychiatric Association. Diagnostic
and statistical manual of mental disorders.Washington (DC): American
Psychiatric Association; 1994.
136.Rumsey JM, Ernst M. Functional neuroimaging
of autistic disorders. Ment Retard Dev Disabil Res Rev 2000;6:171–9.
137.Kemper TL, Bauman M. Neuropathology of infantile
autism. J Neuropathol Exp Neurol 1998;57:645–52.
138.Piven J, Arndt S, Bailey J, Havercamp S, Andreasen
NC, Palmer P. An MRI study of brain size in autism. Am J Psychiatry
1995;152:1145–9.
139.Piven J, Nehme E, Simon J, Barta P, Pearlson
G, Folstein SE. Magnetic resonance imaging in autism: measurement
of the cerebellum, pons, and fourth ventricle. Biol Psychiatry 1992;31:491–504.
140.Courchesne E, Karns CM, Davis HR, Ziccardi R,
Carper RA, Tigue ZD, and others. Unusual brain growth patterns in
early life in patients with autistic disorder: an MRI study. Neurology
2001;57:245–54.
141.Lainhart JE, Piven J, Wzorek M, Landa R, Santangelo
SL, Coon H, and others. Macrocephaly in children and adults with
autism. J Am Acad Child Adolesc Psychiatry 1997;36:282–90.
142.Saitoh O, Karns CM, Courchesne E. Development
of the hippocampal formation from 2 to 42 years: MRI evidence of
smaller area dentata in autism. Brain 2001;124:1317–24.
143.Minshew NJ, Goldstein G, Dombrowski SM, Panchalingam
K, Pettegrew JW. A preliminary 31P MRS study of autism: Evidence
for undersynthesis and increased degradation of brain membranes.
Biol Psychiatry 1993;33:762–73.
144.Hashimoto T, Tayama M, Miyazaki M, Yoneda Y,
Yoshimoto T, Harada M, and others. Differences in brain metabolites
between patients with autism and mental retardation as detected
by in vivo localized proton magnetic resonance spectroscopy. J Child
Neurol 1997;12:91-6.
145.Otsuka H, Harada M, Mori K, Hisaoka S, Nishitani
H. Brain metabolites in the hippocampus-amygdala region and cerebellum
in autism: an 1H-MR spectroscopy study. Neuroradiology 1999;41:517–9.
146.Chugani DC, Sundram BS, Behen M, Lee ML, Moore
GJ. Evidence of altered energy metabolism in autistic children.
Prog Neuropsychopharmacol Biol Psychiatry 1999;23:635–41.
147.Hisaoka S, Harada M, Nishitani H, Mori K. Regional
magnetic resonance spectroscopy of the brain in autistic individuals.
Neuroradiology 2001;43:496–8.
148.Jernigan TL, Zisook S, Heaton RK, Moranville
JT, Hesselink JR, Braff DL. Magnetic resonance imaging abnormalities
in lenticular nuclei and cerebral cortex in schizophrenia. Arch
Gen Psychiatry 1991;48:881–90.
149.Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles
JM, Zipursky RB, Lim KO. A quantitative magnetic resonance imaging
study of changes in brain morphology from infancy to late adulthood.
Arch Neurol 1994;51:874–87.
150.Caviness VS, Jr., Kennedy DN, Richelme C, Rademacher
J, Filipek PA. The human brain age 7-11 years: a volumetric analysis
based on magnetic resonance images. Cereb Cortex 1996;6:726–36.
151. Reiss AL, Abrams MT, Singer HS, Ross JL, Denckla
MB. Brain development, gender and IQ in children. A volumetric imaging
study. Brain 1996;119:1763–74.
152.Giedd JN, Blumenthal J, Jeffries NO, Castellanos
FX, Liu H, Zijdenbos A, and others. Brain development during childhood
and adolescence: a longitudinal MRI study. Nat Neurosci 1999;2:861–3.
153.Stanley JA, Minshew NJ, Keshavan MS, Panchalingam
K, McClure RJ, Pettegrew JW. Assessing the age-dependent profile
in the frontal and centrum semiovale regions of healthy normal controls
using in vivo 31P MRS. Proceedings of the 8th Annual meeting of
the International Society of Magnetic Resonance in Medicine. 2000;
ISMRM: Berkeley (CA). p 1130.
154.De Bellis MD, Keshavan MS, Beers SR, Hall J,
Frustaci K, Masalehdan A, and others. Sex differences in brain maturation
during childhood and adolescence. Cereb Cortex 2001;11:552–7.
155.Riehemann S, Volz HP, Wenda B, Hubner G, Rossger
G, Rzanny R, and others. Frontal lobe in vivo 31P-MRS reveals gender
differences in healthy controls, not in schizophrenics. NMR Biomed
1999;12:483–9.
156.Ross B, Bluml S. Magnetic resonance spectroscopy
of the human brain. Anat Rec 2001;265:54–84.
--------------------------------------------------------------------------------
Manuscript received and accepted March 2002.
1Assistant Professor, Department of Psychiatry,
Western Psychiatric Institute and Clinic, University of Pittsburgh
Medical Center, Pittsburgh, Pennsylvania.
Address for correspondence: Dr JA Stanley, University of Pittsburgh,
Room 721 Parran Hall/GSPH, 130 DeSoto Street, Pittsburgh, PA 15213
e-mail: stanley@pitt.edu
|
